What Is Endomorphin-2? Definition and What Research Reports

Definition

Endomorphin-2 is a short, naturally occurring opioid peptide found in mammalian nervous tissue. It is usually written in the literature as the amidated tetrapeptide Tyr-Pro-Phe-Phe-NH₂ — four amino acids with a capped C-terminus — and it is studied primarily as a ligand at the mu (μ) opioid receptor. A 2006 paper referred to it as an endogenous tetrapeptide while studying it in amyloid-beta models (PMID 16636106), and analogue chemistry papers have described selective μ-opioid receptor activity for modified endomorphin-2 sequences (PMID 34343741). In practice, the word "endomorphin-2" is used in two overlapping ways: for the natural peptide itself, and as a scaffold name for the many synthetic analogues built from it.

What Class of Molecule Is It?

• Class: peptide — specifically an endogenous opioid peptide, distinct from the enkephalin, endorphin and dynorphin families.
• Size: a tetrapeptide, among the shortest endogenous opioid ligands described; positions three and four are both phenylalanine residues, which is why medicinal chemists frequently target them, as in Phe³-Phe⁴-modified peptidomimetics (PMID 24900748).
• Target: the μ-opioid receptor; position-two modifications such as a (R)-γ-Freidinger lactam have been examined for selective μ-opioid receptor activity (PMID 34343741).
• Where it is studied: heavily in spinal cord tissue, where anatomical work has mapped endomorphin-2 alongside spinoparabrachial projection neurons in the rat dorsal horn (PMID 36506871).

How the Term Is Used in Peptide Research

1. Medicinal chemistry and analogue design

The largest share of endomorphin-2 literature is synthetic. Because the native sequence is short and peptidic, groups have published cyclic analogues (PMID 19995587), peptidomimetics carrying modifications at the two phenylalanine positions (PMID 24900748), and lactam-containing analogues evaluated for selective μ-opioid receptor activity (PMID 34343741). A 2007 chemistry paper described the synthesis of endomorphin-2 and its analogues together with analgesic activity testing (PMID 17372948). More recently, researchers applied confocal Raman spectroscopy and imaging as a non-invasive approach to pharmacological profiling of novel endomorphin-2 analogs (PMID 41265349). In these papers the term usually functions as a starting scaffold rather than as the compound actually tested.

2. Spinal cord anatomy and pain circuitry

A second cluster treats endomorphin-2 as an endogenous signalling molecule in the spinal cord. One electrophysiology report described endomorphin-2 decreasing excitatory synaptic transmission in the spinal ventral horn of the rat (PMID 28848403). Morphological work has examined how endomorphin-2-containing elements relate to spinoparabrachial projection neurons in the rat spinal dorsal horn (PMID 36506871). A separate study reported that decreased endomorphin-2 and μ-opioid receptor levels in the spinal cord were associated with painful diabetic neuropathy (PMID 27656127) — an association observed in the study, not a demonstration of cause.

3. Hybrid and chimeric peptides

A third usage is as one half of a fusion construct. Researchers reported a novel endomorphin-2/salmon calcitonin hybrid peptide with enhancing anti-allodynic and anti-anxiety effects (PMID 37778465), and a separate endomorphin-2- and neurotensin-based chimeric peptide was reported to attenuate airway inflammation in a mouse model of nonallergic asthma (PMID 31779093). In both cases the entity studied was the hybrid molecule; endomorphin-2 supplied the opioid pharmacophore.

4. Cell-model and non-analgesia contexts

The name also appears outside pain research. An analogue of endomorphin-2 was reported to inhibit the growth of DLD-1 and RKO human colon cancer cells by inducing cell apoptosis in a laboratory study (PMID 32336747), and an earlier paper described endomorphin-2 as protecting against Aβ_1-42 in vitro and in vivo (PMID 16636106). These are preclinical model systems, and the findings have not been extended to people in the papers summarised here.

What the Published Literature Reports

The table below summarises, in plain terms, what each research context has reported. Every entry reflects the scope of the cited paper and nothing beyond it.

Safety and Tolerability in Endomorphin-2 Research: What Studies Report

The verified papers summarised on this page are chemistry, anatomy, electrophysiology and animal- or cell-model reports; none of them is a human safety trial, and none of them establishes a tolerability profile in people. What they do describe is opioid-receptor pharmacology — for example, the selective μ-opioid receptor activity described for position-two lactam analogues (PMID 34343741) and the analgesic activity testing reported for synthesised endomorphin-2 analogues (PMID 17372948). Because μ-opioid receptor engagement is the shared mechanism across these reports, including the hybrid peptide work (PMID 37778465), readers encountering the term should understand that it belongs to the opioid literature. No adverse-event rates, human exposure data or dosing information appear in the papers cited here, and none are stated on this page. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any substance.

Reading the Term Accurately

1. Check whether the paper studied the native peptide or an analogue. Many titles containing "endomorphin-2" describe modified or hybrid molecules, such as the neurotensin-based chimera (PMID 31779093), not the endogenous tetrapeptide.
2. Check the model. Rat spinal cord slices (PMID 28848403) and human cancer cell lines (PMID 32336747) answer different questions and neither is a clinical result.
3. Check whether the finding is an association. The diabetic neuropathy report described decreased spinal endomorphin-2 and μ-opioid receptor as associated with the pain phenotype (PMID 27656127).
4. Note the analytical method. Newer profiling work used confocal Raman spectroscopy and imaging rather than classical assays alone (PMID 41265349).

Limits of the Evidence

The body of work summarised here is preclinical and largely mechanistic. It describes where endomorphin-2 sits anatomically, how it behaves at a receptor, how chemists have redesigned it, and what happened in specific rodent and cell systems. It does not establish outcomes in humans, and this glossary entry makes no statement about use. Peptide stability, delivery and receptor selectivity remain the recurring technical problems that analogue and peptidomimetic papers set out to address (PMID 24900748, PMID 19995587).

References

• A novel endomorphin-2/salmon calcitonin hybrid peptide with enhancing anti-allodynic and anti-anxiety effects (Peptides, 2023)
• Endomorphin-2- and Neurotensin-Based Chimeric Peptide Attenuates Airway Inflammation in Mouse Model of Nonallergic Asthma (International Journal of Molecular Sciences, 2019)
• Structural and biological exploration of Phe(3)-Phe(4)-modified endomorphin-2 peptidomimetics (ACS Medicinal Chemistry Letters, 2013)
• Endomorphin-2 Analog Inhibits the Growth of DLD-1 and RKO Human Colon Cancer Cells by Inducing Cell Apoptosis (Medical Science Monitor, 2020)
• Selective MOR activity of DAPEA and Endomorphin-2 analogues containing a (R)-γ-Freidinger lactam in position two (Bioorganic Chemistry, 2021)
• Endomorphin-2 Decreases Excitatory Synaptic Transmission in the Spinal Ventral Horn of the Rat (Frontiers in Neural Circuits, 2017)
• Decreased Endomorphin-2 and μ-Opioid Receptor in the Spinal Cord Are Associated with Painful Diabetic Neuropathy (Frontiers in Molecular Neuroscience, 2016)
• Morphological investigations of endomorphin-2 and spinoparabrachial projection neurons in the spinal dorsal horn of the rat (Frontiers in Neuroanatomy, 2022)
• Endomorphin-2, an endogenous tetrapeptide, protects against Abeta1-42 in vitro and in vivo (FASEB Journal, 2006)
• Synthesis and analgesic activities of endomorphin-2 and its analogues (Chemistry & Biodiversity, 2007)
• Non-invasive pharmacological profiling of novel endomorphin-2 analogs by confocal Raman spectroscopy and imaging (Spectrochimica Acta Part A, 2026)
• Synthesis and biological evaluation of cyclic endomorphin-2 analogs (Peptides, 2010)